Levossimendano Reig Jofre (Levosimendan)

Levosimendan works by sensitizing cardiac troponin C to calcium, which enhances the contractile force of the heart without raising intracellular calcium levels. In addition, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering the workload on the heart.

The dosing regimen for levosimendan is determined by the prescribing physician based on the patient’s clinical condition, weight, and response to therapy. The prescriber sets the infusion rate and duration according to approved guidelines and individual patient needs.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan enhances contractility by calcium sensitization, which may reduce the risk of calcium‑related toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that can be advantageous in certain heart‑failure scenarios.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen. It should be kept in its original packaging to maintain stability and prevent contamination. Once removed from refrigeration, use the solution within the time frame specified by the manufacturer.

Levossimendano Reig Jofre is administered intravenously by a healthcare professional. The infusion is typically started with a loading dose followed by a continuous maintenance infusion, with careful monitoring of hemodynamic parameters throughout the treatment period.

The most serious risks include severe hypotension, life‑threatening arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Continuous cardiovascular monitoring is essential to detect and manage these events promptly.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, severe hypotension, obstructive cardiac lesions, or those receiving other strong vasodilators that could cause dangerous blood‑pressure drops. It should also be used with caution in patients with significant renal or hepatic impairment.